Dashboard
Manage Tickers

AZN ASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 80.27 $ 0.00 (0 %)    

Tuesday, 04-Nov-2025 05:27:24 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.66 $ 0.00 (0 %)
DIA $ 469.32 $ 0.00 (0 %)
SPY $ 675.38 $ 0.00 (0 %)
TLT $ 89.98 $ 0.00 (0 %)
GLD $ 367.45 $ 0.00 (0 %)
$ 81.72
$ 82.00
$ 80.23 x 20
$ 80.32 x 500
-- - --
$ 60.82 - $ 86.57
2,896,549
na
126.71B
$ 0.45
$ 7.00
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Governor Of Virginia Says Industry Partner...
10/31/2025 21:01:26

-Reuters

Core News & Articles
Reported Earlier, Daiichi Sankyo And Astra...
10/31/2025 07:53:48

astrazeneca-daiichi-sankyos-datroway-showed-statistically-significant-clinically-meaningful-improvement-for-dual-primary-endpoints-of-overall-survival-progression-free-survival-in-tropion-breast02-phase-3-study-for-recurrent-inoperable-or-metastatic-triple-negative-breast-cancer
AstraZeneca, Daiichi Sankyo's DATROWAY Sho...
10/29/2025 12:14:31

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statis...

Core News & Articles
'US Fires Top Health Official Who Opposed ...
10/28/2025 12:50:58

https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...

eccogene-eyes-hong-kong-ipo-with-experimental-weight-loss-drug-astrazeneca-partnership
Eccogene Eyes Hong Kong IPO With Experimen...
10/23/2025 13:22:01

peering-into-astrazeneca-plcs-recent-short-interest
Peering Into AstraZeneca PLC's Recent Shor...
10/22/2025 14:00:51

the-european-agency-recommends-approving-astrazenecas-saphnelo-as-self-administered-once-weekly-pre-filled-pen-for-systemic-lupus-erythematosus-on-top-of-standard-therapy-8k
The European Agency Recommends Approving A...
10/20/2025 11:16:59

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on interi...

Core News & Articles
Reported Sunday, AstraZeneca And Daiichi S...
10/20/2025 07:36:33

AstraZeneca and Daiichi Sankyo's DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43...

Core News & Articles
Amgen Announces FDA Approval Of TEZSPIRE F...
10/17/2025 20:02:05

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation

invo-fertility-stock-is-plunging-after-white-house-announcement
Invo Fertility Stock Is Plunging After Whi...
10/17/2025 18:37:05

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announceme...

tropion-pantumor03-phase-2-trial-shows-that-datroway-jointly-developed-and-commercialized-by-daiichi-sankyo-and-astrazeneca-reveals-promising-tumor-responses-in-patients-with-metastatic-urothelial-cancer-in-tropion-pantumor03-phase-2-trial-a-confirmed-objective-response-rate-of-682-and-a-disease-control-rate-of-955-was-observed-in-previously-untreated-cisplatin-ineligible-patients
TROPION-PanTumor03 Phase 2 Trial Shows Tha...
10/17/2025 14:13:02

Initial results from one sub-study of the TROPION-PanTumor03 phase 2 trial showed that DATROWAY® (datopotamab deruxtecan) plus ...

astrazeneca-shares-matterhorn-phase-iii-trial-results-for-patients-treated-with-neoadjuvant-imfinzi-in-combination-with-chemotherapy-before-surgery-followed-by-adjuvant-imfinzi-in-combination-with-chemotherapy-then-imfinzi-monotherapy
AstraZeneca Shares MATTERHORN Phase III Tr...
10/17/2025 12:09:28

More than two thirds of patients treated with IMFINZI-based perioperative regimen were alive at three yearsFirst and only perio...

uk-finance-minister-seeks-more-pharma-investment-in-exchange-for-higher-drug-prices-report
UK Finance Minister Seeks More Pharma Inve...
10/16/2025 18:24:06

UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in term...

mercks-keytruda-plus-chemo-regimen-shows-overall-survival-benefit-in-recurrent-ovarian-cancer-patients
Merck's Keytruda Plus Chemo Regimen Shows ...
10/16/2025 14:33:43

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer...

Core News & Articles
Eli Lilly's Oral Weight Loss Drug Shows Su...
10/15/2025 17:24:50

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 ...

hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential
Hedge Fund Shah Capital Urges Novavax To C...
10/14/2025 17:08:17

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

astrazeneca-opens-expanded-manufacturing-facility-in-coppell-texas
AstraZeneca Opens Expanded Manufacturing F...
10/14/2025 14:26:08

AstraZeneca (NASDAQ:AZN) opened its expanded manufacturing facility in Coppell, Texas, following a $445 million investment to d...

astrazeneca-advances-ambition-to-redefine-cancer-care-with-new-data-across-diverse-portfolio-and-pipeline-at-esmo-congress-october-17-21
AstraZeneca Advances Ambition To Redefine ...
10/13/2025 11:03:08

Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab ...

astrazeneca-ceo-soriot-says-negotiated-3-year-tariff-exemption-with-trump-administration
AstraZeneca CEO Soriot Says Negotiated 3-y...
10/10/2025 22:02:00

https://www.youtube.com/watch?v=XOtOCzut9pM

Core News & Articles
President Trump Says AstraZeneca Will List...
10/10/2025 21:41:38

https://www.youtube.com/watch?v=XOtOCzut9pM

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION